The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine

Inclusion Criteria: * Adult patients * Singleton pregnancy * Patients with remaining hypertension despite an oral treatment for who an iv antihypertensive treatment is indicated Patient with PE, as defined by : * Systolic Blood Pressure (BP) ≥ 140 mmHg and/or Diastolic BP ≥ 90 mmHg, after the 20th week of amenorrhea, without chronic hypertension, AND * Proteinuria \> 300 mg.day-1 or \> 2 crosses(++) on an urinary dipstick, OR Patient with severe Pregnancy Induced Hypertension (PIH), as defined by : Systolic BP ≥ 160 mmHg and/or Diastolic BP ≥110 mmHg, after the 20th week of amenorrhea, without chronic hypertension, * Written informed consent signed and dated by both investigator and patient, * Valid social security affiliation Exclusion Criteria: * Known allergy to study drugs * Contra-indication to the study drugs: stenosis of the aortic isthmus, arteriovenous shunt, coarctation of the aorta, unstable angina, compensatory hypertension, myocardial infarction \< 8 days. * Eclampsia * Person with difficulty understanding information * Person with diminished responsibility, * Ongoing intravenous antihypertensive treatment, * No pressure cuff adapted to the morphology of the arms of the patients * Concomitant use of 5 phosphodiesterase inhibitors * Participation in a clinical trial within 6 months prior to inclusion